162 related articles for article (PubMed ID: 23909027)
1. [New approaches to the treatment of breast cancer].
Semiglazov VF
Vopr Onkol; 2013; 59(3):288-91. PubMed ID: 23909027
[No Abstract] [Full Text] [Related]
2. [Strategies of breast cancer treatment based on determination of biological subtype].
Semiglazov VF
Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
[No Abstract] [Full Text] [Related]
3. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
4. [Systemic pharmacotherapy in breast cancer].
Boér K
Orv Hetil; 2004 Jan; 145(4):187-92. PubMed ID: 14978885
[No Abstract] [Full Text] [Related]
5. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
6. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
7. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
[TBL] [Abstract][Full Text] [Related]
8. [Neoadjuvant systemic therapy in breast cancer].
Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
[TBL] [Abstract][Full Text] [Related]
9. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Hrushesky WJ; Retsky M; Baum M; Demicheli R
J Natl Cancer Inst; 2007 Jul; 99(13):1053; author reply 1053-4. PubMed ID: 17596578
[No Abstract] [Full Text] [Related]
10. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
Tuma RS
J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
[No Abstract] [Full Text] [Related]
11. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN
Nat Clin Pract Oncol; 2005 Dec; 2(12):598-9. PubMed ID: 16341096
[No Abstract] [Full Text] [Related]
12. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive breast cancer: current treatment strategies.
Perez EA; Baweja M
Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
[No Abstract] [Full Text] [Related]
14. [Current strategies of primary therapy for breast cancer].
Hayashida T; Jinno H; Sakata M; Takahashi M; Kitagawa Y
Nihon Rinsho; 2010 Jun; 68(6):1137-42. PubMed ID: 20535968
[TBL] [Abstract][Full Text] [Related]
15. Past, present, and future challenges in breast cancer treatment.
Sledge GW; Mamounas EP; Hortobagyi GN; Burstein HJ; Goodwin PJ; Wolff AC
J Clin Oncol; 2014 Jul; 32(19):1979-86. PubMed ID: 24888802
[No Abstract] [Full Text] [Related]
16. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
Láng I; Hitre E
Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
[TBL] [Abstract][Full Text] [Related]
17. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment.
Silverstein MJ; Recht A; Lagios MD; Bleiweiss IJ; Blumencranz PW; Gizienski T; Harms SE; Harness J; Jackman RJ; Klimberg VS; Kuske R; Levine GM; Linver MN; Rafferty EA; Rugo H; Schilling K; Tripathy D; Vicini FA; Whitworth PW; Willey SC
J Am Coll Surg; 2009 Oct; 209(4):504-20. PubMed ID: 19801324
[No Abstract] [Full Text] [Related]
18. HER2 Intermediate Breast Cancers.
Jensen KC; Nielsen TO; Gilks CB; West RB
Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
[No Abstract] [Full Text] [Related]
19. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
Dent R; Clemons M
Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
[No Abstract] [Full Text] [Related]
[Next] [New Search]
